{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:59:25Z","timestamp":1792547965180,"version":"4.5.0"},"reference-count":194,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jaad.2014.05.009","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T22:30:14Z","timestamp":1413325814000},"page":"859.e1-859.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Polycystic ovary syndrome: A review for dermatologists"],"prefix":"10.1016","volume":"71","author":[{"given":"Elizabeth","family":"Buzney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Buzney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel V.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2014.05.009_bib1","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1210\/jc.2007-2437","article-title":"Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline","volume":"93","author":"Martin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib2","first-page":"313","article-title":"Optimizing topical combination therapy for the treatment of acne vulgaris","volume":"11","author":"Zeichner","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2165\/11632500-000000000-00000","article-title":"Newer approaches to the treatment of acne vulgaris","volume":"13","author":"Simonart","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.det.2012.08.005","article-title":"Hair: what is new in\u00a0diagnosis and management? Female pattern hair loss update: diagnosis and treatment","volume":"31","author":"Atanaskova Mesinkovska","year":"2013","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2014.05.009_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejogrb.2004.06.043","article-title":"Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome","volume":"119","author":"Tolino","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jaad.2014.05.009_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1210\/jcem-68-1-173","article-title":"Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss","volume":"68","author":"Pasquali","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib7","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1210\/jc.2004-2490","article-title":"Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome","volume":"90","author":"Gambineri","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib8","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1210\/jc.2002-020815","article-title":"Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome","volume":"88","author":"Moran","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.fertnstert.2003.08.023","article-title":"A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome","volume":"81","author":"Stamets","year":"2004","journal-title":"Fertil Steril"},{"issue":"7","key":"10.1016\/j.jaad.2014.05.009_bib10","first-page":"CD007506","article-title":"Lifestyle changes in women with polycystic ovary syndrome","author":"Moran","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2014.05.009_bib11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jand.2012.11.018","article-title":"Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines","volume":"113","author":"Moran","year":"2013","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.jaad.2014.05.009_bib12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.bjps.2006.11.006","article-title":"Laser hair removal in women with polycystic ovary syndrome","volume":"60","author":"McGill","year":"2007","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.jaad.2014.05.009_bib13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1365-2133.2005.06426.x","article-title":"A randomized controlled trial of laser treatment among hirsute women with polycystic ovary syndrome","volume":"152","author":"Clayton","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1473-2165.2010.00505.x","article-title":"Hyperandrogenism does not predispose patients to photoepilatory treatment failure: a single-center review","volume":"9","author":"Taylor","year":"2010","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/dsu.12116","article-title":"Laser hair removal: a review","volume":"39","author":"Gan","year":"2013","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2014.05.009_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000187718","article-title":"Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome","volume":"218","author":"Rezvanian","year":"2009","journal-title":"Dermatology"},{"issue":"suppl 6","key":"10.1016\/j.jaad.2014.05.009_bib17","first-page":"S1","article-title":"Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men","volume":"9","author":"Blumeyer","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2014.05.009_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2008.07.001","article-title":"Medical treatments for male and\u00a0female pattern hair loss","volume":"59","author":"Rogers","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jaad.2003.06.014","article-title":"A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss","volume":"50","author":"Lucky","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jaad.2010.09.724","article-title":"A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women","volume":"65","author":"Blume-Peytavi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1046\/j.1365-2133.2002.04798.x","article-title":"Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial","volume":"146","author":"Vexiau","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1529-8019.2008.00215.x","article-title":"Medical treatment of hirsutism","volume":"21","author":"Blume-Peytavi","year":"2008","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2014.05.009_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1185\/030079901750176735","article-title":"Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair","volume":"16","author":"Hickman","year":"2001","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaad.2014.05.009_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-4632.2006.03079.x","article-title":"Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair","volume":"46","author":"Wolf","year":"2007","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaad.2006.09.025","article-title":"A randomized bilateral\u00a0vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women","volume":"57","author":"Hamzavi","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/humupd\/dmi005","article-title":"Combined oral contraceptives in the\u00a0treatment of polycystic ovary syndrome","volume":"11","author":"Vrbikova","year":"2005","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.jaad.2014.05.009_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-2007-992931","article-title":"Oral contraceptives in polycystic ovary syndrome:\u00a0risk-benefit assessment","volume":"26","author":"Yildiz","year":"2008","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.jaad.2014.05.009_bib28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/000456328101800407","article-title":"Sex hormone binding globulin: effect of\u00a0synthetic steroids on the assay and effect of oral contraceptives","volume":"18","author":"Bowles","year":"1981","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.jaad.2014.05.009_bib29","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.steroids.2003.08.003","article-title":"All progestins are not created equal","volume":"68","author":"Stanczyk","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.jaad.2014.05.009_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.det.2006.01.002","article-title":"Antiandrogen therapy for skin and hair disease","volume":"24","author":"Harper","year":"2006","journal-title":"Dermatol Clin"},{"issue":"3 suppl","key":"10.1016\/j.jaad.2014.05.009_bib31","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1016\/S0010-7824(98)00079-1","article-title":"Uniqueness of oral contraceptive progestins","volume":"58","author":"Carr","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2014.05.009_bib32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/106002809502907-817","article-title":"Desogestrel, norgestimate, and gestodene: the newer progestins","volume":"29","author":"Kaplan","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2014.05.009_bib33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2337\/dc06-2227","article-title":"Androgenicity of progestins in hormonal contraceptives and the risk of gestational diabetes mellitus","volume":"30","author":"Hedderson","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaad.2014.05.009_bib34","first-page":"105","article-title":"Initiating hormonal contraception","volume":"74","author":"Lesnewski","year":"2006","journal-title":"Am\u00a0Fam Physician"},{"key":"10.1016\/j.jaad.2014.05.009_bib35","first-page":"1499","article-title":"Managing adverse effects of hormonal contraceptives","volume":"82","author":"Grossman Barr","year":"2010","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jaad.2014.05.009_bib36","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1210\/jcem-26-12-1370","article-title":"Treatment of hirsutism by adrenal and ovarian suppression","volume":"26","author":"Casey","year":"1966","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2265.1985.tb01061.x","article-title":"The treatment of hirsutism with a combination of desogestrel and ethinyl oestradiol","volume":"22","author":"Dewis","year":"1985","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jaad.2014.05.009_bib38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/00016348509155112","article-title":"Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome","volume":"64","author":"Cullberg","year":"1985","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jaad.2014.05.009_bib39","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1210\/jc.2003-031158","article-title":"Drospirenone for the treatment of hirsute women with\u00a0polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study","volume":"89","author":"Guido","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib40","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.fertnstert.2005.07.1311","article-title":"Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism","volume":"85","author":"Batukan","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib41","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0015-0282(16)54291-5","article-title":"Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives","volume":"55","author":"Porcile","year":"1991","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib42","first-page":"109","article-title":"Treatment of hirsutism in polycystic ovarian syndrome with Diane, 50mcg ethinyl estradiol and 2mg cyproterone acetate","volume":"9","author":"Saeed","year":"1993","journal-title":"Pakistan J Med Sci"},{"key":"10.1016\/j.jaad.2014.05.009_bib43","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0015-0282(02)02993-X","article-title":"Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives","volume":"77","author":"Mastorakos","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0010-7824(03)00027-1","article-title":"Efficacy\u00a0of\u00a0second versus third generation oral contraceptives in the treatment of hirsutism","volume":"67","author":"Breitkopf","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2014.05.009_bib45","series-title":"Oral contraception: realizing the promise by overcoming the pitfalls. Individualizing oral contraceptive therapy. OBG management supplement","first-page":"2","author":"Dickey","year":"2000"},{"issue":"7","key":"10.1016\/j.jaad.2014.05.009_bib46","first-page":"CD004425","article-title":"Combined oral contraceptive pills for treatment of acne","author":"Arowojolu","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2014.05.009_bib47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2340\/0001555564517523","article-title":"Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives","volume":"64","author":"Palatsi","year":"1984","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2014.05.009_bib48","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1067\/mob.2003.294","article-title":"A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris","volume":"188","author":"Rosen","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jaad.2014.05.009_bib49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.contraception.2003.12.017","article-title":"Cycle control, quality of\u00a0life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol","volume":"69","author":"Winkler","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2014.05.009_bib50","first-page":"23","article-title":"Desogestrel+ethinylestradiol versus levonorgestrel+ethinylestradiol. Which one has better affect on acne, hirsutism, and weight change","volume":"32","author":"Sanam","year":"2011","journal-title":"Saudi Med J"},{"key":"10.1016\/j.jaad.2014.05.009_bib51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1447-0756.2011.01682.x","article-title":"Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome","volume":"38","author":"Bhattacharya","year":"2012","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.jaad.2014.05.009_bib52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.contraception.2005.07.010","article-title":"Treating acne with oral contraceptives: use of lower doses","volume":"73","author":"Huber","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2014.05.009_bib53","first-page":"2073","article-title":"Update on oral contraceptive pills","volume":"60","author":"Cerel-Suhl","year":"1999","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jaad.2014.05.009_bib54","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/01443610400007810","article-title":"Polycystic ovary syndrome, diabetes and cardiovascular disease: risk and risk factors","volume":"24","author":"Lakhani","year":"2004","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.jaad.2014.05.009_bib55","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2002-021528","article-title":"A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills","volume":"88","author":"Diamanti-Kandarakis","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib56","first-page":"3327","article-title":"Metabolic effects of oral contraceptives in women with polycystic ovary syndrome","volume":"80","author":"Korytkowski","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1742-1241.2008.01877.x","article-title":"Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome","volume":"63","author":"Soares","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jaad.2014.05.009_bib58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/humrep\/deg056","article-title":"Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome","volume":"18","author":"Ibanez","year":"2003","journal-title":"Hum Reprod"},{"issue":"4","key":"10.1016\/j.jaad.2014.05.009_bib59","first-page":"CD001125","article-title":"Cyproterone acetate for hirsutism","author":"Van der Spuy","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2014.05.009_bib60","doi-asserted-by":"crossref","first-page":"f5298","DOI":"10.1136\/bmj.f5298","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis","volume":"347","author":"Stegeman","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2014.05.009_bib61","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2014.05.009_bib62","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2014.05.009_bib63","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal\u00a0contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2014.05.009_bib64","doi-asserted-by":"crossref","first-page":"d2139","DOI":"10.1136\/bmj.d2139","article-title":"Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database","volume":"342","author":"Parkin","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2014.05.009_bib65","doi-asserted-by":"crossref","first-page":"d2151","DOI":"10.1136\/bmj.d2151","article-title":"Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral\u00a0contraceptives containing levonorgestrel: case-control study using United States claims data","volume":"342","author":"Jick","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2014.05.009_bib66","doi-asserted-by":"crossref","first-page":"E1319","DOI":"10.1503\/cmaj.110463","article-title":"Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study","volume":"183","author":"Gronich","year":"2011","journal-title":"CMAJ"},{"key":"10.1016\/j.jaad.2014.05.009_bib67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.contraception.2012.09.015","article-title":"Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users","volume":"87","author":"Sidney","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2014.05.009_bib68","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/pds.1554","article-title":"Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores","volume":"17","author":"Eng","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaad.2014.05.009_bib69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1783\/147118910791749416","article-title":"Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study","volume":"36","author":"Dinger","year":"2010","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.jaad.2014.05.009_bib70","unstructured":"US Food and Drug Administration web site. Drospirenone-containing combination oral contraceptives briefing document 2011. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM282464.pdf. Accessed July 25, 2013."},{"key":"10.1016\/j.jaad.2014.05.009_bib71","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jfprhc-2012-100297","article-title":"Difference between drospirenone-containing oral contraceptives and other oral contraceptives related to risk of venous thromboembolism","volume":"38","author":"Leppee","year":"2012","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.jaad.2014.05.009_bib72","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1600-0412.2012.01444.x","article-title":"Hormonal\u00a0contraception and venous thromboembolism","volume":"91","author":"Lidegaard","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jaad.2014.05.009_bib73","first-page":"358","article-title":"Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome","volume":"36","author":"Carmina","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jaad.2014.05.009_bib74","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1503\/cmaj.120677","article-title":"Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis","volume":"185","author":"Bird","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.jaad.2014.05.009_bib75","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1001\/archinte.164.18.1965","article-title":"Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review","volume":"164","author":"Gomes","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaad.2014.05.009_bib76","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/jth.12224","article-title":"Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?","volume":"11","author":"Bird","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jaad.2014.05.009_bib77","unstructured":"US Food and Drug Administration web site. Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. Available at: http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm299305.htm. Accessed February 8, 2014."},{"key":"10.1016\/j.jaad.2014.05.009_bib78","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/1471-0528.12210","article-title":"Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review","volume":"120","author":"Wu","year":"2013","journal-title":"BJOG"},{"key":"10.1016\/j.jaad.2014.05.009_bib79","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","article-title":"Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study","volume":"143","author":"Heit","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2014.05.009_bib80","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/09513590.2011.613971","article-title":"Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome","volume":"28","author":"Karabulut","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib81","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.fertnstert.2012.06.035","article-title":"Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome","volume":"98","author":"Bhattacharya","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib82","first-page":"258","article-title":"Clinical efficacy of low dose flutamide plus Diane-35 in the treatment of idiopathic hirsutism and polycystic ovary syndrome","volume":"84","author":"Boztosun","year":"2013","journal-title":"Ginekol Pol"},{"key":"10.1016\/j.jaad.2014.05.009_bib83","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.contraception.2010.02.009","article-title":"Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome","volume":"82","author":"Kriplani","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2014.05.009_bib84","first-page":"2","article-title":"The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea","volume":"69","author":"van Vloten","year":"2002","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2014.05.009_bib85","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.contraception.2008.10.010","article-title":"Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol\/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035\u00a0mg ethinylestradiol\/2 mg cyproterone acetate","volume":"79","author":"Palombo-Kinne","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2014.05.009_bib86","unstructured":"US National Institutes of Health web site. Comparison of efficacy and safety of norgestimate-thyinyl estradiol and cyproterone acetate-ethinyl estradiol in the treatment of acne vulgaris. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00752635. Accessed July 7, 2013."},{"key":"10.1016\/j.jaad.2014.05.009_bib87","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1783\/1471189041261636","article-title":"An observational study of Yasmin in the management of women with polycystic ovary syndrome","volume":"30","author":"Palep-Singh","year":"2004","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.jaad.2014.05.009_bib88","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.contraception.2007.11.003","article-title":"Efficacy and safety of 3 mg drospirenone\/20 mcg ethinylestradiol oral contraceptive administered in 24\/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial","volume":"77","author":"Koltun","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2014.05.009_bib89","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/AOG.0b013e318187e1c5","article-title":"Treatment of acne using a 3-milligram drospirenone\/20-microgram ethinyl estradiol oral contraceptive administered in a 24\/4 regimen: a randomized controlled trial","volume":"112","author":"Maloney","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jaad.2014.05.009_bib90","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1468-3083.2011.04292.x","article-title":"Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation","volume":"26","author":"Colonna","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2014.05.009_bib91","first-page":"123","article-title":"Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment","volume":"74","author":"Thorneycroft","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2014.05.009_bib92","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0015-0282(16)48373-1","article-title":"The\u00a0effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women","volume":"43","author":"Lobo","year":"1985","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib93","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0010-7824(94)00015-O","article-title":"Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models","volume":"51","author":"Muhn","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2014.05.009_bib94","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/120347540200600604","article-title":"Long-term safety of spironolactone in acne: results of an 8-year followup study","volume":"6","author":"Shaw","year":"2002","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2014.05.009_bib95","doi-asserted-by":"crossref","first-page":"e4447","DOI":"10.1136\/bmj.e4447","article-title":"Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study","volume":"345","author":"Mackenzie","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2014.05.009_bib96","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00128071-200708040-00003","article-title":"Dermatologic manifestations of polycystic ovary syndrome","volume":"8","author":"Lee","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib97","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.0.1470467","article-title":"Comparison of high-dose finasteride (5 mg\/day) versus low-dose finasteride (2.5 mg\/day) in the treatment of hirsutism","volume":"147","author":"Bayram","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib98","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1530\/eje.0.1410361","article-title":"Comparison of finasteride versus flutamide in the treatment of hirsutism","volume":"141","author":"Falsetti","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib99","first-page":"89","article-title":"Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial","volume":"85","author":"Moghetti","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/09513590009167658","article-title":"Treatment of hirsutism with lowest-dose flutamide (62.5 mg\/day)","volume":"14","author":"Muderris","year":"2000","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib101","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF03343536","article-title":"Clinical efficacy of lower dose flutamide 125 mg\/day in the treatment of hirsutism","volume":"22","author":"Muderris","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jaad.2014.05.009_bib102","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/humrep\/dei004","article-title":"Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women","volume":"20","author":"Ibanez","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jaad.2014.05.009_bib103","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1210\/jc.2007-2430","article-title":"Clinical review: antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials","volume":"93","author":"Swiglo","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib104","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0015-0282(16)57727-9","article-title":"Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism","volume":"64","author":"Ciotta","year":"1995","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/gye.17.1.57.63","article-title":"The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism","volume":"17","author":"Lakryc","year":"2003","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib106","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/pgmj.65.765.459","article-title":"Lack of effect of spironolactone on hair shaft diameter in hirsute females","volume":"65","author":"McLellan","year":"1989","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jaad.2014.05.009_bib107","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2265.2004.01973.x","article-title":"Effect of flutamide and metformin administered alone or in combination in dieting\u00a0obese women with polycystic ovary syndrome","volume":"60","author":"Gambineri","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jaad.2014.05.009_bib108","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.numecd.2013.04.016","article-title":"In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone","volume":"24","author":"Mazza","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jaad.2014.05.009_bib109","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1210\/jc.2013-1040","article-title":"Improved efficacy of low dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six month, open label randomized study","volume":"98","author":"Ganie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2265.2012.04466.x","article-title":"Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome","volume":"78","author":"Harmanci","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jaad.2014.05.009_bib111","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/014107688607900806","article-title":"Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome","volume":"79","author":"Evans","year":"1986","journal-title":"J R Soc Med"},{"key":"10.1016\/j.jaad.2014.05.009_bib112","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1345\/aph.1G025","article-title":"Spironolactone for hirsutism in polycystic ovary syndrome","volume":"39","author":"Christy","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.jaad.2014.05.009_bib113","first-page":"CD000194","article-title":"Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne","author":"Brown","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2014.05.009_bib114","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0015-0282(00)00470-2","article-title":"A prospective, randomized trial comparing flutamide (250 mg\/d) and finasteride (5\u00a0mg\/d) in the treatment of hirsutism","volume":"73","author":"Muderris","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0015-0282(16)56518-2","article-title":"Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial","volume":"61","author":"Cusan","year":"1994","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib116","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2133.1986.tb05722.x","article-title":"Oral spironolactone: an effective treatment for acne vulgaris in women","volume":"115","author":"Muhlemann","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib117","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/archderm.134.9.1162-a","article-title":"Adverse effects of spironolactone therapy in women with acne","volume":"134","author":"Lubbos","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib118","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1067\/mjd.2000.105557","article-title":"Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients","volume":"43","author":"Shaw","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib119","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2133.1984.tb04045.x","article-title":"Oral spironolactone improves acne vulgaris and reduces sebum excretion","volume":"111","author":"Goodfellow","year":"1984","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2007.09.024","article-title":"Efficacy and tolerance of acne\u00a0treatment using both spironolactone and a combined contraceptive containing drospirenone","volume":"58","author":"Krunic","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib121","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMcp072110","article-title":"Clinical practice. Hair loss in women","volume":"357","author":"Shapiro","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2014.05.009_bib122","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2133.2005.06218.x","article-title":"Treatment of female pattern hair loss with oral antiandrogens","volume":"152","author":"Sinclair","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib123","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/archderm.142.3.298","article-title":"Finasteride treatment of female pattern hair loss","volume":"142","author":"Iorizzo","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib124","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000079890","article-title":"Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women","volume":"209","author":"Tr\u00fceb","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2014.05.009_bib125","first-page":"317","article-title":"Quantitative assessment of spironolactone treatment in women with diffuse androgen dependant alopecia","volume":"42","author":"Rushton","year":"1991","journal-title":"J Soc Cosmet Chem"},{"key":"10.1016\/j.jaad.2014.05.009_bib126","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/09513590903215581","article-title":"Clinical, metabolic, and endocrine parameters in\u00a0response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial","volume":"26","author":"Fux Otta","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib127","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/GCO.0b013e32833e1264","article-title":"Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update","volume":"22","author":"Katsiki","year":"2010","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.jaad.2014.05.009_bib128","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1517\/14728220903190699","article-title":"Targeting insulin sensitivity in the treatment of polycystic ovary syndrome","volume":"13","author":"Pasquali","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaad.2014.05.009_bib129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4239\/wjd.v2.i3.33","article-title":"Assessing and treating insulin resistance in women with polycystic ovarian syndrome","volume":"2","author":"Traub","year":"2011","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jaad.2014.05.009_bib130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/eje.0.1470217","article-title":"The effect of metformin on hirsutism in polycystic ovary syndrome","volume":"147","author":"Kelly","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib131","first-page":"3251","article-title":"Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide","volume":"85","author":"Ibanez","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib132","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0015-0282(00)00501-X","article-title":"Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome","volume":"73","author":"Kolodziejczyk","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib133","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1210\/jcem.85.8.6738","article-title":"Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome","volume":"85","author":"Pasquali","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib134","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(03)13493-9","article-title":"Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome","volume":"361","author":"Harborne","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2014.05.009_bib135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/gye.17.1.51.56","article-title":"Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome","volume":"17","author":"Kazerooni","year":"2003","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib136","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/09513590500231627","article-title":"The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome","volume":"21","author":"Yilmaz","year":"2005","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib137","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0029-1237705","article-title":"The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome","volume":"118","author":"Oppelt","year":"2010","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.jaad.2014.05.009_bib138","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.fertnstert.2009.01.114","article-title":"Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial","volume":"93","author":"Romualdi","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib139","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpedi.160.3.241","article-title":"Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome","volume":"160","author":"Bridger","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.jaad.2014.05.009_bib140","first-page":"444","article-title":"Metformin & glitazones: do they really help PCOS patients?","volume":"56","author":"Pillai","year":"2007","journal-title":"J Fam Pract"},{"key":"10.1016\/j.jaad.2014.05.009_bib141","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2002-020997","article-title":"Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study","volume":"88","author":"Morin-Papunen","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib142","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0015-0282(98)00011-9","article-title":"Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome","volume":"69","author":"Morin-Papunen","year":"1998","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.jaad.2014.05.009_bib143","first-page":"CD005552","article-title":"Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome","author":"Costello","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2014.05.009_bib144","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/09513590701192529","article-title":"Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity","volume":"23","author":"Marcondes","year":"2007","journal-title":"Gynecol Endocrinol"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2014.05.009_bib145","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.fertnstert.2006.04.014","article-title":"Use of antiandrogens as therapy for women with polycystic ovary syndrome","volume":"86","author":"Moghetti","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib146","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clindermatol.2006.04.004","article-title":"Dermatology of androgen-related disorders","volume":"24","author":"Essah","year":"2006","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2008-0030","article-title":"Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review","volume":"30","author":"Palomba","year":"2009","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jaad.2014.05.009_bib148","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1210\/jc.2007-2429","article-title":"Insulin sensitizers for the treatment of\u00a0hirsutism: a systematic review and meta-analyses of randomized controlled trials","volume":"93","author":"Cosma","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib149","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2265.2008.03472.x","article-title":"Low dose pioglitazone and low dose flutamide added to metformin and oestro progestagens for hyperinsulinaemic women with androgen excess: add on benefits disclosed by a randomized double placebo study over 24 months","volume":"71","author":"Ib\u00e1\u00f1ez","year":"2009","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib150","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1530\/EJE-07-0294","article-title":"Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance","volume":"157","author":"Tan","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib151","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2265.2012.04415.x","article-title":"Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome","volume":"78","author":"Cinar","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.jaad.2014.05.009_bib152","first-page":"CD003053","article-title":"Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility","author":"Tang","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2014.05.009_bib153","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/jc.2007-0282","article-title":"Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome","volume":"92","author":"Luque-Ram\u00edrez","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib154","first-page":"3161","article-title":"Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study","volume":"85","author":"Morin-Papunen","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib155","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/AOG.0b013e3181bd12cb","article-title":"ACOG Practice Bulletin No. 108: polycystic ovary syndrome","volume":"114","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.jaad.2014.05.009_bib156","first-page":"CD003053","article-title":"Insulin-sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome","author":"Lord","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2014.05.009_bib157","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/humupd\/dmi054","article-title":"Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women","volume":"12","author":"Iba\u00f1\u00e9z","year":"2006","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.jaad.2014.05.009_bib158","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1530\/eje.1.02156","article-title":"Insulin-sensitizing agents in polycystic ovary syndrome","volume":"154","author":"Pasquali","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib159","first-page":"1","article-title":"Polycystic ovary syndrome and acne","volume":"15","author":"Chuan","year":"2010","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.jaad.2014.05.009_bib160","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1210\/er.2002-0015","article-title":"Insulin-lowering agents in the management of polycystic ovary syndrome","volume":"24","author":"De Leo","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jaad.2014.05.009_bib161","first-page":"884","article-title":"Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study","volume":"5","author":"Bellot-Rojas","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib162","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ncpendmet0787","article-title":"Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome\u00f3a reappraisal","volume":"4","author":"Dunaif","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib163","first-page":"1626","article-title":"Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multi-center, double-blind, placebo-controlled trial","volume":"86","author":"Azziz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib164","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0015-0282(98)00454-3","article-title":"Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome","volume":"71","author":"Hasegawa","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib165","first-page":"2108","article-title":"Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome","volume":"82","author":"Ehrmann","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib166","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","article-title":"Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2014.05.009_bib167","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1517\/14740338.2013.741585","article-title":"Examining the safety of PPAR agonists - current trends and future prospects","volume":"12","author":"Bortolini","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaad.2014.05.009_bib168","doi-asserted-by":"crossref","first-page":"d1309","DOI":"10.1136\/bmj.d1309","article-title":"Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies","volume":"342","author":"Loke","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2014.05.009_bib169","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0015-0282(02)04843-4","article-title":"Effect\u00a0of\u00a0rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome","volume":"79","author":"Ghazeeri","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib170","first-page":"1618","article-title":"Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin","volume":"18","author":"Glueck","year":"2003","journal-title":"Hum\u00a0Reprod"},{"key":"10.1016\/j.jaad.2014.05.009_bib171","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/humrep\/deg264","article-title":"Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinemic obese patients with polycystic ovary syndrome","volume":"18","author":"Romualdi","year":"2003","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jaad.2014.05.009_bib172","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3109\/09513590.2010.491572","article-title":"Thiazolinedione treatment in PCOS-an update","volume":"26","author":"Glintborg","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib173","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1507\/endocrj.52.299","article-title":"Endocrine\u00a0and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease","volume":"52","author":"Dereli","year":"2005","journal-title":"Endocr J"},{"key":"10.1016\/j.jaad.2014.05.009_bib174","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2004-1965","article-title":"Responses of serum\u00a0androgen and insulin resistance to metformin and\u00a0pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome","volume":"90","author":"Ortega-Gonz\u00e1lez","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib175","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.fertnstert.2004.02.127","article-title":"Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity","volume":"82","author":"Baillargeon","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib176","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8019.2006.00077.x","article-title":"Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome","volume":"19","author":"Lowenstein","year":"2006","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2014.05.009_bib177","doi-asserted-by":"crossref","first-page":"402.e1","DOI":"10.1016\/j.ajog.2006.12.025","article-title":"The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome","volume":"196","author":"Legro","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jaad.2014.05.009_bib178","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.fertnstert.2005.07.1312","article-title":"A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome","volume":"85","author":"Rouzi","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib179","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2265.2010.03917.x","article-title":"Metformin vs thiazolidinediones for treatment of clinical,\u00a0hormonal and metabolic characteristics of polycystic ovary syndrome: a meta analysis","volume":"74","author":"Li","year":"2011","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib180","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2165\/00003495-200969110-00001","article-title":"The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome","volume":"69","author":"Katsiki","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2014.05.009_bib181","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/humrep\/dei505","article-title":"Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study","volume":"21","author":"Rautio","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jaad.2014.05.009_bib182","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/09513590.2011.583958","article-title":"Pioglitazone reduces central obesity in polycystic ovary syndrome women","volume":"28","author":"Asadipooya","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib183","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","article-title":"Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS Consensus Workshop Group","volume":"97","author":"Fauser","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib184","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0015-0282(02)04927-0","article-title":"Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism","volume":"79","author":"Lumachi","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2014.05.009_bib185","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0190-9622(99)70408-1","article-title":"Recurrence rate of hirsutism after 3 different antiandrogen therapies","volume":"41","author":"Yucelten","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib186","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-4632.2012.05691.x","article-title":"Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse","volume":"52","author":"Cakir","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib187","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2265.2010.03934.x","article-title":"When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?","volume":"74","author":"Franks","year":"2011","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jaad.2014.05.009_bib188","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tem.2007.08.001","article-title":"The management of insulin resistance in polycystic ovary syndrome","volume":"18","author":"Teede","year":"2007","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jaad.2014.05.009_bib189","first-page":"111","article-title":"Polycystic ovary syndrome: a dermatologic approach","volume":"86","author":"Moura","year":"2011","journal-title":"An\u00a0Bras Dermatol"},{"key":"10.1016\/j.jaad.2014.05.009_bib190","first-page":"209","article-title":"Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth","volume":"68","author":"Harwood","year":"2007","journal-title":"Horm Res"},{"key":"10.1016\/j.jaad.2014.05.009_bib191","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/humupd\/dmp024","article-title":"Visually scoring hirsutism","volume":"16","author":"Yildiz","year":"2010","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.jaad.2014.05.009_bib192","series-title":"Oral contraceptives today: changes, challenges, risks, and benefits","author":"Grimes","year":"2007"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2014.05.009_bib193","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/13697130500330382","article-title":"Pharmacology of different progestogens: the special case of drospirenone","volume":"8","author":"Sitruk-Ware","year":"2005","journal-title":"Climacteric"},{"key":"10.1016\/j.jaad.2014.05.009_bib194","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.maturitas.2008.11.011","article-title":"Pharmacological profile of progestins","volume":"61","author":"Sitruk-Ware","year":"2008","journal-title":"Maturitas"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214014376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962214014376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:32:31Z","timestamp":1759271551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962214014376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":194,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0190962214014376"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2014.05.009","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polycystic ovary syndrome: A review for dermatologists","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2014.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}